Investing.com UK - Financial Markets Worldwide
NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Bristol-Myers buys private drugmaker to boost heart treatment pipeline

Published 02/11/2015, 15:20
© Reuters. Bristol-Myers buys private drugmaker to boost heart treatment pipeline
BMY
-

By Vidya L Nathan

(Reuters) - Bristol-Myers Squibb Co (N:BMY) said on Monday it bought privately held drug developer Cardioxyl Pharmaceuticals Inc in a deal worth up to $2.07 billion (1.33 billion pound), to gain access to a heart failure treatment.

Bristol-Myers said Cardioxyl's CXL-1427, which is in mid-stage studies, would add to its basket of heart treatments that include three experimental treatments in early- and mid-stage studies.

At least 5.1 million Americans suffer from heart failure, for which there is no cure, according to the Centers for Disease Control and Prevention.

CXL-1427 works by releasing the chemical compound nitroxyl and relaxing the heart muscle, helping it expand and improving blood flow, Bristol-Myers said in a statement.

The company said it would pay up $300 million upfront and that it expected the deal to hurt full-year profit by 12 cents per share.

Bristol-Myers shares closed at $65.95 on Friday. OLGBBUS Reuters UK Online Report Business News 20151102T121948+0000

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.